来自山地种植的人参残留物的新型葡萄糖可以保护2型糖尿病患者的症状诱导心力衰竭
Zhuoran Li1, Dongyue Zhou1, Tongchuan Wu1
1Changchun University of Chinese Medicine, Changchun 130117, China.
Journal of ethnopharmacology
|August 24, 2024
概括
从Panax人参残留物中获得的一种新型糖,APMCG-1,在细胞模型和斑马鱼中显示出对心力衰竭的显著保护作用. 这一发现为新的基于糖的心脏病治疗提供了潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 山地种植的帕纳克斯人参C.A.Mey. (MCG) 是一种有价值的传统医药,历史上用于心力衰竭 (HF).
- 关于MCG残留提取物的治疗作用的研究有限.
- 在中国传统医学中,HF被认为是"心脏"的缺陷.
研究的目的:
- 从MCG残留物中分离和描述一种新型糖.
- 为了评估体外和体内隔离的葡萄糖的心脏保护作用.
- 探索其治疗作用的潜在机制.
主要方法:
- 通过蛋白酶辅助提取和乙醇沉,分离了一种新型糖 (APMCG-1).
- 使用FT-IR,HPLC和GPC分析了分子量和亚单元结构.
- 使用棕酸诱导的H9c2细胞和2型糖尿病的斑马鱼模型来评估保护作用.
主要成果:
- 鉴定出APMCG-1是一种由七个单糖和七个氨基酸组成的糖.
- 在体外,APMCG-1减少了H9c2细胞中的活性氧物种和乳酸脱酶,减弱了内分泌网膜应激,并通过PI3K/AKT通路抑制了线粒体介导的亡.
- 在体内,APMCG-1改善了心脏功能,降低了血糖和脂质水平,并在2型糖尿病症状的斑马鱼中减少了氧化应激和炎症.
结论:
- APMCG-1对H9c2细胞的棕酸诱导损伤具有显著的心脏保护作用.
- 在2型糖尿病的斑马鱼模型中,APMCG-1在减少心脏功能障碍方面表现出有效性.
- 这项研究强调了APMCG-1作为一种新型糖治疗心脏相关疾病的潜力.
相关概念视频
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:06Oral Hypoglycemic Agents: Glinides
149
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149